PT  - JOURNAL ARTICLE
AU  - Jagadeesh Kumar, V
AU  - Sowpati, Divya Tej
AU  - Munigela, Apoorva
AU  - Banu, Sofia
AU  - Siva, Archana Bharadwaj
AU  - Sasikala, M
AU  - Nutalapati, Chandrasekhar
AU  - Kulkarni, Anand
AU  - Mukherjee, Payel
AU  - Zaveri, Lamuk
AU - CCMB COVID-19 Team
AU - AIG Hospitals COVID-19 Vaccine study Team
AU  - Tallapaka, Karthik Bharadwaj
AU  - Reddy, D Nageshwar
TI  - Clinical outcomes in vaccinated individuals hospitalized with Delta variant of SARS-CoV-2
AID  - 10.1101/2021.07.13.21260417
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.07.13.21260417
4099  - http://medrxiv.org/content/early/2021/07/16/2021.07.13.21260417.short
4100  - http://medrxiv.org/content/early/2021/07/16/2021.07.13.21260417.full
AB  - Emerging variants of SARS-CoV-2 with increased transmissibility or immune escape have been causing large outbreaks of COVID-19 infections across the world. As most of the vaccines currently in use have been derived from viral strains circulating in the early part of the pandemic, it becomes imperative to constantly assess the efficacy of these vaccines against emerging variants. In this hospital-based cohort study, we analysed clinical profiles and outcomes of 1161 COVID-19 hospitalized patients (vaccinated with COVISHIELD (ChAdOx1) or COVAXIN (BBV-152), n = 495 and unvaccinated n = 666) in Hyderabad, India between April 24th and May 31st 2021. Viral genome sequencing revealed that >90% of patients in both groups were harbouring the Delta variant (Pango lineage B.1.617.2) of SARS-CoV-2. Vaccinated individuals showed higher neutralizing antibodies (545±1256 AU/ml Vs 51.1±296 AU/ml; p<0.001) and significantly decreased Ferritin (392.26 ± 448.4 ng/mL Vs 544.82 ± 641.41 ng/mL; p<0.001) and LDH (559.45 ± 324.05 U/L Vs 644.99 ± 294.03 U/L; p<0.001), when compared to the unvaccinated group. Severity of the disease (3.2% Vs 7.2%; p=0.0039) and requirement of ventilatory support (2.8% Vs 5.9%; p=0.0154) were significantly low in the vaccinated group despite the fact that these individuals had significantly higher age and risk factors. The rate of mortality was about 50% lower (2/132=1.51%) in the completely vaccinated breakthrough infections although mortality in individuals who had received a single dose was similar to the unvaccinated group (9/269=3.35% vs 23/666= 3.45%). Our results demonstrate that both COVISHIELD and COVAXIN are effective in preventing disease severity and mortality against the Delta variant in completely vaccinated hospitalized patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study is supported by the CSIR grant MLP0128 and intramural funds from Asian Healthcare Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Approved by DCGI registered Institutional Ethics Committee of AIG Hospitals, Hyderabad, IndiaAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data is available with the corresponding Author from AIG Hospitals and is available upon request